P.A.W. Capital Corp Galmed Pharmaceuticals Ltd. Transaction History

P.A.W. Capital Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	SELL	$0.44 - $1.77 $88,000 - $354,000	-200,000 Closed	0 $0
Q3 2020 Nov 09, 2020	BUY	$3.46 - $5.69 $346,000 - $569,000	100,000 Added 100.0%	200,000 $706,000
Q4 2019 Jan 28, 2020	BUY	$3.61 - $6.75 $108,300 - $202,500	30,000 Added 42.86%	100,000 $578,000
Q2 2019 Jul 31, 2019	SELL	$5.68 - $8.68 $113,600 - $173,600	-20,000 Reduced 22.22%	70,000 $515,000
Q3 2018 Oct 24, 2018	SELL	$10.55 - $15.28 $52,750 - $76,400	-5,000 Reduced 5.26%	90,000 $1.22 Million
Q2 2018 Jul 25, 2018	SELL	$5.04 - $17.96 $25,200 - $89,800	-5,000 Reduced 5.0%	95,000 $1.13 Million
Q1 2018 Apr 26, 2018	SELL	$5.12 - $11.77 $25,600 - $58,850	-5,000 Reduced 4.76%	100,000 $557,000
Q3 2017 Oct 23, 2017	BUY	$7.36 - $9.29 $772,800 - $975,449	105,000	105,000 $960,000

Ticker GLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,088,400
Market Cap $91.6M
Description
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or t...

Get notified when there are updates to the investment portfolio of P.A.W. Capital Corp, based on Form 13F filings with the SEC.

Stay updated on P.A.W. Capital Corp with notifications on news.